Handelsbanken Fonder AB Buys 69,440 Shares of Gilead Sciences, Inc. $GILD

Handelsbanken Fonder AB lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.3% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,164,320 shares of the biopharmaceutical company’s stock after purchasing an additional 69,440 shares during the quarter. Handelsbanken Fonder AB’s holdings in Gilead Sciences were worth $129,088,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Activest Wealth Management increased its position in shares of Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares during the period. GoalVest Advisory LLC grew its stake in Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares in the last quarter. Harbor Asset Planning Inc. purchased a new position in Gilead Sciences during the second quarter valued at approximately $27,000. Putney Financial Group LLC increased its holdings in Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 94 shares during the period. Finally, Colonial Trust Advisors lifted its stake in Gilead Sciences by 304.3% in the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 213 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $124.99 on Friday. The stock’s 50-day moving average is $118.23 and its 200 day moving average is $113.37. The stock has a market cap of $155.07 billion, a price-to-earnings ratio of 24.90, a P/E/G ratio of 0.81 and a beta of 0.32. Gilead Sciences, Inc. has a 1-year low of $88.07 and a 1-year high of $128.70. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $125.23, for a total value of $313,075.00. Following the completion of the sale, the chief financial officer owned 154,555 shares of the company’s stock, valued at approximately $19,354,922.65. The trade was a 1.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Deborah H. Telman sold 53,646 shares of the stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total value of $6,590,411.10. Following the sale, the executive vice president owned 43,676 shares of the company’s stock, valued at $5,365,596.60. This represents a 55.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 125,146 shares of company stock valued at $15,148,441. Corporate insiders own 0.27% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on GILD shares. Royal Bank Of Canada boosted their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the company a “sector perform” rating in a research report on Friday, October 31st. Morgan Stanley boosted their target price on Gilead Sciences from $143.00 to $147.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Citigroup raised their price target on Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a report on Wednesday, October 8th. Scotiabank started coverage on Gilead Sciences in a report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price objective for the company. Finally, Daiwa Capital Markets upped their price objective on shares of Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a research report on Thursday, November 13th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $130.45.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.